Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting
June 09 2008 - 7:00AM
Business Wire
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today
data from a Phase II clinical trial demonstrating that its ultra
rapid acting intranasal insulin was both superior to usual therapy
(oral anti-diabetic medicines and/or basal insulin) and
non-inferior to insulin aspart (NovoLog�), a rapid-acting
injectable insulin, in maintaining glucose control at both 60 and
90 minutes following a meal. The data also demonstrated a
statistically significant reduction in the incidence of
hypoglycemia (low blood sugar
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Historical Stock Chart
From May 2024 to Jun 2024
Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Historical Stock Chart
From Jun 2023 to Jun 2024